The average one-year price target for Immunome (NasdaqCM:IMNM) has been revised to $34.94 / share. This is an increase of 33.44% from the prior estimate of $26.18 dated December 3, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $26.26 to a high of $42.00 / share. The average price target represents an increase of 62.94% from the latest reported closing price of $21.44 / share.
What is the Fund Sentiment?
There are 308 funds or institutions reporting positions in Immunome. This is an increase of 16 owner(s) or 5.48% in the last quarter. Average portfolio weight of all funds dedicated to IMNM is 0.17%, an increase of 10.00%. Total shares owned by institutions increased in the last three months by 13.64% to 99,864K shares. 
The put/call ratio of IMNM is 0.33, indicating a bullish outlook.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 8,418K shares representing 9.18% ownership of the company. In its prior filing, the firm reported owning 8,275K shares , representing an increase of 1.70%. The firm increased its portfolio allocation in IMNM by 24.00% over the last quarter.
Redmile Group holds 5,023K shares representing 5.48% ownership of the company. In its prior filing, the firm reported owning 4,872K shares , representing an increase of 3.01%. The firm increased its portfolio allocation in IMNM by 18.68% over the last quarter.
Point72 Asset Management holds 4,825K shares representing 5.26% ownership of the company. In its prior filing, the firm reported owning 4,686K shares , representing an increase of 2.87%. The firm increased its portfolio allocation in IMNM by 10.52% over the last quarter.
Enavate Sciences GP holds 4,769K shares representing 5.20% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 4,079K shares representing 4.45% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
